Nucleoside phosphoramidates
Disclosed herein are nucleoside phosphoramidates and their use as agents for treating viral diseases. These compounds are inhibitors of RNA-dependent RNA viral replication and are useful as inhibitors of HCV NS5B polymerase, as inhibitors of HCV replication and for treatment of hepatitis C infection in mammals.
1. A crystalline compound represented by the formula (S P -4):
having XRPD 2θ-reflections (°) at about: 6.1 and 12.7.
2. A pharmaceutical composition comprising the crystalline compound according to claim 1 and a pharmaceutically acceptable medium.
3. A method of treating a hepatitis C virus infection in a human comprising administering to the human an effective amount of the crystalline compound according to claim 1 .
4. The method according to claim 3 further comprising administering to the human another antiviral agent.
5. A process for preparing the crystalline compound according to claim 1 comprising:
exposing a second crystalline compound represented by the formula (S P -4):
having an XRPD diffraction pattern substantially as shown in FIG. 3 or FIG. 4 to atmospheric humidity to provide a first composition.
6. The process according to claim 5 further comprising:
grinding the first composition into a powder; and
allowing the powder to stand in an open vessel.
7. A process for preparing the crystalline compound according to claim 1 comprising:
suspending a second crystalline compound represented by the formula (S P -4):
having an XRPD diffraction pattern substantially as shown in FIG. 3 or FIG. 4 in water to provide a suspension.
8. The process according to claim 7 further comprising heating the suspension.
9. The process according to claim 8 further comprising cooling the suspension.